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Abstract
We have determined the in vitro and in vivo cellular distribution of the
antineoplastic agent paclitaxel (Taxol) in human blood and the influence
of Cremophor EL (CrEL), the vehicle used for i.v. drug administration. In
the absence of CrEL, the blood:plasma concentration ratio was
1.07 6 0.004 (mean 6 SD). The addition of CrEL at concentrations
corresponding to peak plasma levels achieved after the administration of
paclitaxel (175 mg/m2 i.v. over a 3-h period; i.e., 0.50%) resulted in a
significant decrease in the concentration ratio (0.690 6 0.005; P < 0.05).
Kinetic experiments revealed that this effect was caused by reduced
erythrocyte uptake of paclitaxel by polyoxyethyleneglycerol triricinoleate,
the major compound present in CrEL. Using equilibrium dialysis, it was
shown that the affinity of paclitaxel for tested matrices was (in decreasing
order) CrEL > plasma > human serum albumin, with CrEL present at or
above the critical micellar concentration (;0.01%). Our findings in the
present study demonstrate a profound alteration of paclitaxel accumula-
tion in erythrocytes caused by a trapping of the compound in CrEL
micelles, thereby reducing the free drug fraction available for cellular
partitioning. It is proposed that the nonlinearity of paclitaxel plasma
disposition in patients reported previously should be reevaluated prospec-
tively by measuring the free drug fractions and whole blood:plasma
concentration ratios.
Introduction
A substantial number of clinical studies with the antineoplastic
agent paclitaxel (Taxol) have been performed to date and have re-
vealed a nonlinear disposition of the drug, which may have significant
implications in that greater-than-expected increases in systemic expo-
sure may result from a given increase in dose (1). For example, 3-h
infusions of paclitaxel at 135 mg/m2 resulted in a mean Cmax2 of 3.3
mM and a mean AUC of 10.4 mMzh, whereas at 175 mg/m2, the mean
Cmax and AUC values were 5.9 and 18.0 mMzh, respectively (2). Thus,
a 30% increase in dose results in an 80% increase in the Cmax and a
75% increase in the AUC. In line with results from dose escalation
studies in humans, paclitaxel disposition in mice also increased dis-
proportionally with doses increasing from 2 to 10 or 20 mg/kg (3).
Subsequent studies have demonstrated that both distribution and elim-
ination appeared to be linear processes in the absence of CrEL, the
formulation vehicle used for i.v. drug administration (4). Because
plasma concentrations of CrEL in mice and humans are within the
same range, it is very likely that CrEL also plays an important role in
nonlinear paclitaxel disposition in humans (5, 6). At present, the
biochemical mechanisms responsible for the dose-dependent interac-
tion of CrEL with the pharmacokinetics of paclitaxel remain unclear.
It has been suggested that CrEL might interfere with P-glycoprotein-
mediated biliary drug secretion, thereby influencing paclitaxel elimi-
nation (7). However, recent studies indicate that drug-transporting
P-glycoproteins are not essential per se for normal hepatobiliary
secretion of paclitaxel (8, 9) and that the disposition of CrEL itself
limits the potential to modulate P-glycoprotein activity in vivo (10).3
In the present study, we have determined the in vitro and in vivo
cellular distribution of paclitaxel in human blood in an effort to extend
our insight into the role of CrEL in the pharmacokinetics of paclitaxel.
Materials and Methods
Chemicals and Reagents. Paclitaxel powder and a sterile solution of
paclitaxel formulated in a mixture of CrEL and dehydrated ethanol USP (1:1,
v/v) at 6 mg/ml were obtained from the Bristol-Myers Squibb Co. (Walling-
ford, CT). Stock solutions of paclitaxel at 1 mg/ml in DMSO were stored at
280°C and diluted further in methanol-DMSO (1:1, v/v) before use. CrEL,
pure castor oil, and human serum albumin (fraction V) standards were obtained
from Sigma Chemical Co. (St. Louis, MO), and Coomassie Brilliant Blue
G-250 was obtained from Bio-Rad Laboratories (Munich, Germany) as a
concentrated solution in 85% (w/v) phosphoric acid-ethanol (2:1, v/v). Five
reversed-phase HPLC fractions of crude CrEL, each with progressively in-
creased hydrophobicity, were kindly donated by Dr. David Kessel (Wayne
State University, Detroit, MI; Ref. 11). Miscellaneous chemicals and reagents
were of the highest grade available and originated from Rathburn (Walkerburn,
United Kingdom). Purified water was obtained by filtration and deionization
using a Milli-Q-UF system (Millipore, Bedford, MA) and was used through-
out.
Experimental Techniques. Samples of human blood were obtained from
four healthy volunteers in glass vials containing lyophilized sodium heparin as
an anticoagulant and were used within 1 h after collection. Aliquots of the
blood were centrifuged for 5 min at 3000 3 g (4°C) to separate plasma, which
was transferred to a clean polypropylene tube and then stored frozen at 220°C
until used. Erythrocyte suspensions were prepared with freshly donated hep-
arinized blood from which the plasma and buffy coat were removed by
aspiration. The cells were washed twice, each time with 3 ml of ice-cold
phosphate buffer containing 0.01 M potassium phosphate, 0.137 M sodium
chloride, and 2.7 mM potassium chloride, in the presence of 0.05% (w/v)
glucose at pH 7.4 and resuspended in the same buffer to give the desired
hematocrit. For preparation of platelet-rich plasma, heparinized blood was
centrifuged at 200 3 g for 20 min at room temperature to pack down the
erythrocytes and leukocytes. The resulting supernatant, with very low contam-
ination from RBCs and leukocytes, was used as platelet-rich plasma.
Blood:plasma ratio experiments were conducted using aliquots (2 ml) of the
various matrices, which were placed in a 37°C shaking water bath for 5 min
before the addition of paclitaxel in the presence or absence of CrEL. At the
time required for maximal cellular paclitaxel uptake at equilibrium, duplicate
aliquots of 250 ml were withdrawn from the incubation tubes (Eppendorf,
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Hamburg, Germany) and kept at 280°C for 5 min to achieve complete
hemolysis. The remaining blood fraction was centrifuged, and the supernatant
was diluted 4-fold with drug-free human plasma to determine plasma concen-
trations as described above.
Equilibrium dialysis was accomplished at 37°C in a humidified atmosphere
of 5% CO2 using test cells made from 1.5-ml polypropylene microtubes
(Eppendorf) carrying a 250-ml inside recess in the lids. The experiments were
carried out with 250-ml aliquots of paclitaxel-containing (1 mg/ml) plasma or
a 40 mg/ml solution of human serum albumin in 0.01 M phosphate buffer (pH
7.4) against an equal volume of the same buffer. Spectra/Por 3 dialysis tubing
with a Mr 12,500 cutoff (Spectrum Medical, Kitchener, Canada) was soaked in
0.9% (w/v) sodium chloride solution before use. The time to reach equilibrium
was determined in preliminary experiments and ranged between 5 and 24 h,
depending on the composition of the fluid in the receptor compartment. The
ratio of drug concentrations measured by HPLC in the buffer and plasma or
serum albumin solution after dialysis was taken as an estimate of the unbound
(free) fraction of paclitaxel. Because the volume shift during dialysis was
negligible (,10%), the results were used directly without applying a correction
factor. In both the blood:plasma ratio and equilibrium dialysis experiments, it
was confirmed that the total drug recovery from all of the fractions was equal
to the amount of paclitaxel added to blood, plasma, or buffer mixtures.
Clinical Pharmacokinetics. The patient studied was a 65-year-old female
suffering from recurrent ovarian cancer after earlier cisplatin-containing chem-
otherapy. She received paclitaxel formulated in CrEL-ethanol at an absolute
dose of 256 mg supplemented with 100 mCi of [G-3H]paclitaxel (specific
activity, 2.4 Ci/mmol; radiochemical purity, 99.7% by HPLC; Moravek Bio-
chemicals, Inc., Brea, CA). The majority of the tritium is in the m- and
p-positions of the aromatic rings, with minor amounts in the 10-, 39-, and 2-
position of the taxane ring system. The dose was administered as a 3-h i.v.
infusion in 500 ml of sterile and isotonic sodium chloride, after a standard
premedication comprising dexamethasone (10 mg, i.v.), clemastine (2 mg, i.v.)
and ranitidine (50 mg, i.v.). Blood samples (;5 ml) were obtained in glass
tubes with lyophilized sodium heparin at the following time points: immedi-
ately before dosing; at 0.5, 1, 1.5, 2, 2.5, and 3 h after start of infusion; and at
5, 15, 30, and 45 min and 1, 2, 4, 6, 8, 12, and 24 h after end of infusion.
Aliquots (1 ml) of whole blood were immediately stored frozen at 220°C, and
the remaining blood was centrifuged at 4000 3 g for 5 min to separate plasma.
The clinical protocol was approved by the Rotterdam Cancer Institute Ethics
Board, and the patient gave informed consent before study entry. Concentra-
tions of paclitaxel were measured using an isocratic reversed-phase HPLC
method with UV detection at 230 nm, as described previously (12). The
analytical procedure for CrEL was based on a colorimetric dye-binding assay
using Coomassie Brilliant Blue G-250 (13), with modifications as described
(6).
Results
In Vitro Partition in Blood Fractions. The time to equilibrium of
paclitaxel between whole blood and plasma, as determined by meas-
uring the concentration on blood cells at several time points at 37°C
and calculating the rate of migration, was reached within 15 min of
pooling cells and plasma. At this time point, a blood:plasma ratio of
1.07 6 0.004 (mean 6 SD) was observed, which was independent of
the paclitaxel concentration, indicating that the cellular concentration
is proportional to the concentration in plasma water. This shows that
the rate of exchange between blood cells and plasma water is effec-
tively instantaneous on the time scale of paclitaxel disposition and that
the steady-state load on cells represents approximately half of the total
blood concentration. The addition of CrEL at concentrations corre-
sponding to peak plasma levels achieved after the administration of
paclitaxel (175 mg/m2 i.v. over a 3-h period; i.e., 0.50%; Ref. 10)
resulted in a significant decrease in the blood:plasma concentration
ratio (0.690 6 0.005; P , 0.05). Additional experiments revealed a
clear concentration-dependent effect of CrEL on this ratio, with max-
imal inhibition of cellular paclitaxel uptake at a CrEL total blood
concentration of 1.0% (Table 1). At this concentration, the blood:
plasma ratio averaged 0.625 6 0.008, suggesting a distribution of
paclitaxel merely outside blood cells, with ;88% of total paclitaxel
associated with the plasma fraction, assuming a mean hematocrit of
0.45. Incubation of paclitaxel in whole blood with castor oil, the major
component in the CrEL vehicle before polyoxyethylation, showed no
evidence of significant alterations in cellular uptake with a mean
blood:plasma ratio of 1.23 6 0.17 (P . 0.05). Experiments with
reversed-phase HPLC fractions of CrEL indicated that the effect of
the unfractionated vehicle was not observed with the hydrophilic
components present in the first fractions, which mainly contained
polyethylene glycol and oxyethylated glycerol (Table 1), but is pri-
marily caused by compounds from fraction 4, e.g., polyoxyethylene-
glycerol triricinoleate along with fatty acid esters of polyethylene
glycol.
The distribution of paclitaxel within an artificial mixture of washed
erythrocytes occupying 45% of the total volume and buffer indicated
RBC:buffer concentration ratios of 3.70 6 0.061 and 0.649 6 0.014
in the absence and presence of CrEL, respectively, further indicating
that in the latter case, paclitaxel is only distributed in the water phase
(Table 2). The apparent contradiction between the low blood:plasma
ratio and high accumulation into erythrocytes was shown to be due to
the compensating effect of plasma protein binding, which has been
observed previously for a variety of other drugs (for an overview, see
Ref. 14), including paclitaxel (15). This is borne out by the finding
that in the presence of plasma proteins, cellular partitioning of pacli-
taxel in erythrocytes was markedly impaired (Table 2). Surprisingly,
paclitaxel accumulation in platelets was less affected by CrEL than
erythrocyte uptake (Table 2), with a platelet:plasma ratio in the order
of ;300, taking into account the low total platelet volume in blood
(;4 ml/ml blood). As suggested recently by Wild et al. (16), this high
degree of platelet uptake likely reflects a tight binding of paclitaxel to
the intracellular tubulin/microtubule system and has previously been
Table 1 Blood:plasma concentration ratio of paclitaxel in the absence and presence of
various concentrations of CrEL, castor oil, and HPLC fractions of CrELa
Compound added (%) Blood:plasma ratio
Percentage change
vs. control (%) Pb
None 1.07 6 0.004
CrEL (0.01) 1.09 6 0.009 11.83 0.387
CrEL (0.05) 0.990 6 0.015 29.35 0.012
CrEL (0.10) 0.901 6 0.017 215.8 0.003
CrEL (0.50) 0.690 6 0.005 235.5 ,0.0001
CrEL (1.0) 0.625 6 0.008 241.6 ,0.0001
Castor oil (0.50) 1.23 6 0.171 113.0 0.061
CrEL fraction 1 (0.50) 1.06 6 0.008 20.94 0.520
CrEL fraction 2 (0.50) 0.926 6 0.018 213.5 0.043
CrEL fraction 3 (0.50) 0.763 6 0.055 228.7 0.010
CrEL fraction 4 (0.50) 0.645 6 0.051 239.7 0.003
CrEL fraction 5 (0.50) 0.943 6 0.039 211.9 0.103
a Paclitaxel was used at an initial concentration of 1 mg/ml and incubated in whole
blood for 15 min at 37°C before fractionation and HPLC analysis. Ratio data are presented
as mean values 6 SD of (at least) triplicate measurements.
b Probability value versus control (unpaired two-sided Student’s t test).
Table 2 Distribution of paclitaxel in artificial binary mixture systems of the main
blood fractions in the absence and presence of CrELa
Binary system CrEL (%) Total:extracellular ratio
Percentage change
vs. control (%) Pb
Erythrocytes/bufferc None 3.70 6 0.061
0.50 0.649 6 0.014 282.5 ,0.001
Erythrocytes/plasmac None 1.03 6 0.021
0.50 0.664 6 0.007 235.5 0.002
Platelets/plasmad None 1.33 6 0.037
0.50 1.26 6 0.024 25.26 0.018
a Paclitaxel was used at an initial concentration of 1 mg/ml and incubated in whole
blood for 15 min at 37°C before fractionation and HPLC analysis. Ratio data are presented
as mean values 6 SD of (at least) triplicate measurements.
b Probability value versus control (unpaired two-sided Student’s t test).
c Hematocrit, ;0.45.
d Platelet count, ;750 3 109/L.
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shown to occur with other tubulin-interactive drugs, such as the Vinca
alkaloids (16).
Binding Interactions. To gain insight into the mechanism under-
lying this phenomenon, equilibrium dialysis was used to determine the
effects of CrEL on the fraction of unbound paclitaxel. Preliminary
experiments verified that CrEL could not cross the semipermeable
dialysis membrane, as indicated by the absence of detectable levels in
the buffer compartment after dialysis. As predicted by earlier exper-
iments (5), paclitaxel was found to bind extensively to human plasma
(89.1 6 0.595%, mean 6 SD; n 5 3) in the absence of CrEL, with
human serum albumin accounting for approximately 50% of the total
binding. In the presence of CrEL (0.50%), however, a clear and
statistically significant decrease in the free (unbound) drug fraction of
up to 66% (P 5 0.013) and 92% (P 5 0.002) was seen for plasma and
human serum albumin, respectively. Interestingly, equilibrium dialy-
sis experiments performed with CrEL in the absence of any plasma
proteins revealed that at a spiked concentration of 0.50%, a free drug
fraction of only 0.044 was observed, suggesting that paclitaxel affinity
for CrEL is substantially greater than that for either plasma or human
serum albumin. This binding affinity for CrEL was distinctly concen-
tration dependent, with no change in the free fraction of paclitaxel at
CrEL concentrations below 0.01% [i.e., the amount of surfactant
corresponding to the critical micellar concentration in aqueous solu-
tions (17)] and maximal binding (at a free drug fraction of ;0.017) in
the presence of CrEL at a concentration of 1.0%. Equilibrium dialysis
of paclitaxel-containing plasma against a buffer with CrEL resulted in
a virtually quantitative shift of drug (90.1 6 1.09%) to the receptor
fluid, further pointing to a preferential binding to the surfactant.
In Vivo Pharmacokinetics. Fig. 1 shows the logarithmic concen-
tration-time curves of paclitaxel in whole blood and plasma (i.e., the
unbound ultrafiltrate fraction plus the protein/CrEL-bound blood frac-
tion; Fig. 1A) and of CrEL in plasma (Fig. 1B) after an i.v. dose of 256
mg was administered to a female patient with advanced ovarian
cancer. Similar to our in vitro partition experiments, a distinct CrEL
concentration dependency was noted for the whole blood:plasma
concentration ratio and the unbound drug fraction (Table 3). This
suggests that erythrocytes form a secondary transport system in whole
blood, which becomes less significant as the CrEL concentration
increases; hence, the unbound drug concentration decreases. In all,
these data appear to indicate that CrEL micelles act as the principal
carrier of paclitaxel in the systemic circulation.
Discussion
In the present study, we have shown that CrEL, the formulation
vehicle used for i.v. drug administration, causes a profound alteration
of paclitaxel accumulation in erythrocytes by reducing the free drug
fraction available for cellular partitioning. This effect was also ob-
served in the absence of plasma proteins, indicating that it was not
caused by altered protein binding or an increased affinity of paclitaxel
for protein dissociation products that are produced by the action of
CrEL on native lipoproteins (11, 18). The data indicate that erythro-
cytes form a secondary transport system in whole blood, which
becomes less significant as the CrEL concentration increases, and
hence, the free drug fraction decreases. Current data suggest that drug
trapping occurs in micelles composed primarily of polyoxyethylene-
glycerol triricinoleate and that these micelles act as the principal
carrier of paclitaxel in the systemic circulation.
The findings of extensive RBC uptake of paclitaxel at low CrEL
levels and the high binding to plasma proteins and CrEL micelles may
have a substantial impact on the interpretation of the drug’s pharma-
cokinetic behavior that has not been fully appreciated. Previously,
paclitaxel disposition in animals and humans has been reported to be
nonlinear, with disproportional relationships between changes in the
dose and the resulting plasma AUCs and peak plasma concentrations.
This nonlinearity has been speculated to result from two separate
saturable processes, one in distribution and one in elimination (both
described by Michaelis-Menten kinetics), based on the usefulness of
complex mathematical pharmacokinetic models to accurately describe
plasma profiles of paclitaxel over a wide dosage range (1, 2). The
authors have generated estimates of the maximal process rate (i.e.,
Vmax) and the paclitaxel concentration associated with 0.5 3 Vmax
(i.e., Km) and observed that the Km estimate for the distribution
process is much smaller than that for elimination. This suggested that
distribution should be the first process to exhibit saturation. Our
present data indicate that the resulting disproportional accumulation
of paclitaxel in plasma, which is most pronounced with the drug
administered by the 3-h infusion schedule (1), is related to a CrEL-
mediated alteration of drug distribution within the circulation during
paclitaxel infusion. This is exactly what is observed clinically in our
patient and is supported by our previous finding that, in spite of
nonlinear paclitaxel kinetics in plasma, tissue levels of the parent drug
and its known mono- and dihydroxylated metabolites in mice have a
linear relationship with the dose administered (3). The paradox of
disproportional increases in plasma concentrations and linear distri-
bution processes in tissues is likely caused by the fact that the plasma
comprises a relatively small fraction of the total volume available for
paclitaxel distribution and that, simultaneously, the CrEL-drug com-
plex is not stable enough to substantially reduce the amount of drug
that exists in the body in the active, diffusible, unbound form. In
addition, it is also possible that the equilibrium between blood and
tissues is not based solely on paclitaxel dissolved in the plasma water
phase but also on direct drug transport from loaded erythrocytes to
Fig. 1. Concentration versus time curves of paclitaxel in whole blood (E) and plasma
(F; A) and of CrEL (f) in plasma (B). Pharmacokinetic data were obtained from a female
patient receiving the drug formulated at 6 mg/ml in a mixture of CrEL-dehydrated ethanol
USP (1:1, v/v) at an absolute dose of 256 mg.
Table 3 CrEL concentration-dependent blood:plasma ratio and unbound paclitaxel
fraction in plasma of a patienta
Time (h)b CrEL (%) Blood:plasma ratio Unbound fraction
0.50 0.039 1.02 0.076
1.0 0.122 0.795 0.057
1.5 0.157 0.851 0.038
2.0 0.215 0.749 0.028
2.5 0.300 0.737 0.022
3.0 0.335 0.623 0.016
a Paclitaxel was administered as an i.v. infusion over a 3-h period at an absolute dose
of 256 mg to a single female with advanced ovarian cancer.
b Sample collection time point after the start of a 3-h i.v. infusion of paclitaxel.
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tissues (14). This hypothetical transport may be of great importance
for paclitaxel in cases of low concomitant CrEL levels that are
associated with low dose schedules. Regardless of the uptake pro-
cesses of the tissues, our current findings indicate that the operation of
Michaelis-Menten kinetics, the postulated cause of nonlinear pacli-
taxel disposition in plasma, is not related to saturable tissue binding or
disproportional elimination kinetics but appears to be an artifact
caused by paclitaxel dose-related levels of CrEL in the blood. We are
currently prospectively reevaluating the linearity of paclitaxel phar-
macokinetics in humans using different infusion schedules by meas-
uring free drug fractions and blood:plasma ratios, based on the ex-
pectation that if the fraction of drug that is bound changes appreciably
with concentration in the concentration range of interest, then the
AUC of free (unbound) paclitaxel should be a linear function of the
dose administered.
The existence of CrEL in blood as large polar micelles with a
highly hydrophobic interior also raises the possibility of additional
complexities in case of combination chemotherapy regimens with
paclitaxel. For example, fluorescence studies on the interaction be-
tween anthracycline drugs and different surfactants indicated that
daunorubicin, although relatively hydrophilic with an octanol:water
partition ratio of ;3.5, is readily incorporated into CrEL micelles
(17). Thus, in the systemic circulation, micellar incorporation of
anthracyclines may result in altered cellular distribution and a con-
comitantly increased plasma concentration. In this regard, it is inter-
esting to note that both paclitaxel (in the clinical formulation) and
CrEL alone strongly affect the plasma pharmacokinetics of another
anthracycline antineoplastic agent, doxorubicin, in both rodents and
humans (7, 19). Similarly, CrEL is known to decrease etoposide
clearance in rats (20), and preliminary findings in humans treated with
a combination of paclitaxel ($175 mg/m2 over a 3-h period) and i.v.
etoposide confirmed these observations.4 At present, we are investi-
gating the effects of micellar incorporation on the biodistribution and
pharmacokinetics of doxorubicin and etoposide and the role of CrEL
as a determinant of the increased incidence and severity of hemato-
logical toxicity in clinical trials (7) with a combination of paclitaxel
and doxorubicin.5
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